Sonoma Pharmaceuticals (SNOA) Non-Current Deffered Revenue (2011 - 2025)
Sonoma Pharmaceuticals' (SNOA) quarterly Non-Current Deffered Revenue came in at $24000.0 in Q2 2025, down 62.5% year-on-year from $64000.0 in Q2 2024, and down 67.12% quarter-over-quarter from $73000.0 in Q1 2025.
Sonoma Pharmaceuticals (SNOA) Non-Current Deffered Revenue (2011 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' Non-Current Deffered Revenue history runs 15 years deep, the most recent figure standing at $24000.0 for Q2 2025.
- On a quarterly basis, Non-Current Deffered Revenue fell 62.5% year-over-year to $24000.0 in Q2 2025; TTM through Jun 2025 was $24000.0, a 62.5% decrease from a year earlier, with the FY2025 full-year figure at $73000.0, down 77.88% from the prior year.
- Non-Current Deffered Revenue retreated to $24000.0 in Q2 2025 per SNOA's latest filing, from $73000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $330000.0 in Q1 2024 and bottomed at $24000.0 in Q2 2025.
- The 5-year median for Non-Current Deffered Revenue is $139000.0 (2022), against an average of $146444.4.
- Across the five-year window, Non-Current Deffered Revenue jumped 135.71% in 2024 and sank 77.88% in 2025, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $190000.0 in 2021, then sank by 32.63% to $128000.0 in 2022, then dropped by 21.09% to $101000.0 in 2023, then plunged by 70.3% to $30000.0 in 2024, then dropped by 20.0% to $24000.0 in 2025.
- Per Business Quant, the three latest SNOA Non-Current Deffered Revenue figures stand at $24000.0 (Q2 2025), $73000.0 (Q1 2025), and $30000.0 (Q4 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 24,000.00 |
| Mar 31, 2025 | 73,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Sep 30, 2024 | 179,000.00 |
| Jun 30, 2024 | 64,000.00 |
| Mar 31, 2024 | 330,000.00 |
| Dec 31, 2023 | 101,000.00 |
| Sep 30, 2023 | 114,000.00 |
| Jun 30, 2023 | 132,000.00 |
| Mar 31, 2023 | 140,000.00 |
| Dec 31, 2022 | 128,000.00 |
| Sep 30, 2022 | 138,000.00 |
| Jun 30, 2022 | 152,000.00 |
| Mar 31, 2022 | 182,000.00 |
| Dec 31, 2021 | 190,000.00 |
| Sep 30, 2021 | 205,000.00 |
| Jun 30, 2021 | 225,000.00 |
| Mar 31, 2021 | 229,000.00 |
| Dec 31, 2020 | 251,000.00 |
| Sep 30, 2020 | 235,000.00 |